Kasinger's sales were made under a Rule 10b5-1 plan adopted on May 6, 2026.
Rhea-AI Filing Summary
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share, acquired 10,400 shares, and sold 10,400 shares at a weighted average price of $60.2365 per share. The sales were made under a Rule 10b5-1 trading plan adopted May 6, 2026. The option transaction reported 83,232 shares following the exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,400 shares ($485K approx. pre-tax spread)
Holdings After Transaction: Stock Option (Right to Buy) โ 83,232 contracts (Direct); Common Shares โ 94,784 shares (Direct)
Footnotes (4)
- F1. Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Key Figures
Options exercised: 10,400 options Exercise price: $13.62 per share Common shares acquired: 10,400 shares +3 more
Options exercised 10,400 options September 22, 2026
Exercise price $13.62 per share Options exercised September 22, 2026
Common shares acquired 10,400 shares September 22, 2026
Common shares sold 10,400 shares September 22, 2026
Weighted average sale price $60.2365 per share Sale on September 22, 2026
Shares following option exercise 83,232 shares Reported following the September 22, 2026 transaction
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy)
Rule 10b5-1 trading plan regulatory
"Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many CRSP options did James R. Kasinger exercise, and at what price?
He exercised options covering 10,400 common shares on September 22, 2026, at an exercise price of $13.62 per share. The option transaction reported 83,232 shares following the exercise.
When were the CRSP options originally granted, and what was their vesting schedule?
The option was granted on May 31, 2017, with respect to 123,000 common shares. The footnote states that 25% shall vest on May 31, 2018, and the remaining 75% shall vest monthly thereafter for 36 months.
AI-generated analysis. How Rhea-AI works. Not financial advice.